ImmunoAct’s NexCAR19 Achieves 98% MRD Negativity in India with Significant Cost Reduction Compared to Western CAR-T Therapies

August 9, 2026

Citeline Scrip India

Overview

ImmunoAct’s CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), achieved a 98% minimal residual disease (MRD) negativity rate in real-world Indian data, delivering comparable efficacy to Western CAR-T therapies at a significantly lower cost. This robust real-world evidence, derived from India’s largest CAR-T dataset, validates its manufacturing, delivery, efficacy, and safety, positioning it as a globally accessible and scalable model. This breakthrough promises to enhance CAR-T accessibility and affordability, addressing unmet medical needs worldwide.

In Depth

Key Findings

ImmunoAct’s CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), has demonstrated remarkable real-world effectiveness in India, achieving an impressive 98% minimal residual disease (MRD) negativity rate. Critically, this therapy delivers efficacy comparable to leading Western CAR-T treatments but at a significantly lower cost, offering a scalable and globally accessible model for advanced cellular immunotherapy.

Technical / Clinical Details

NexCAR19 is an autologous CAR-T cell therapy, where a patient’s own T cells are genetically engineered to target the CD19 antigen present on cancer cells. Real-world evidence from India’s largest CAR-T dataset comprehensively supports the success of NexCAR19 across manufacturing, delivery, efficacy, and safety. The 98% MRD negativity rate is a powerful indicator, signifying that cancer cells are virtually undetectable post-treatment, which is strongly correlated with prolonged remission and improved overall survival. This cost-effective treatment addresses a major barrier to access for CAR-T therapies in developing nations and economically constrained regions. The safety profile, including incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), has been shown to be comparable to that of Western-approved products, further solidifying its clinical utility.

Background & Context

While CAR-T cell therapies have revolutionized the treatment of specific hematological malignancies like B-cell lymphomas and leukemias, their high cost, complex manufacturing processes, and limited global accessibility remain significant challenges. In countries like India, the financial and logistical barriers to importing and administering Western CAR-T products are substantial, preventing many patients from accessing this life-saving treatment. ImmunoAct’s NexCAR19 overcomes these challenges by leveraging a localized supply chain and manufacturing infrastructure, enabling the provision of high-quality, yet affordable, CAR-T therapy. This represents a crucial step towards establishing a ‘globally accessible and scalable model’ for CAR-T cell therapy.

Strategic Significance & Outlook

The success of NexCAR19 is poised to have a profound impact on the global dissemination of CAR-T therapy. The combination of its high MRD negativity rate and significant cost reduction offers a compelling blueprint for other nations to develop their own CAR-T manufacturing capabilities and expand patient access. ImmunoAct is expected to continue expanding its clinical data and exploring additional indications, thereby reaching more patients with this innovative treatment. Furthermore, this achievement demonstrates that advanced medical technologies need not be prohibitively expensive; rather, localized innovation can help bridge the global healthcare equity gap, making transformative therapies available to a broader population.

Source: https://insights.citeline.com/scrip/focus-on-asia/india/immunoacts-car-t-real-world-report-card-durable-remissions-98-msr-FA7TNDTVV5CVPMHDGNKIPOFTAM/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.